Alert detail
FDA Approval: FETROJA (CEFIDEROCOL SULFATE TOSYLATE) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA209445Specialty: Infectious DiseaseAdded: 7/8/2026Effective: November 14, 2019billing update
What changed
New FDA drug approval. Coverage and billing pathway depend on the FDA label and applicable Medicare LCDs/NCDs — for very recent approvals the label may not be posted yet. Verify against the FDA label and current coverage policy before billing.
Who’s affected: Infectious Disease billing teams · Effective: November 14, 2019
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.